Sulzer Medica launches biological implant in Europe:
This article was originally published in Clinica
Sulzer Medica has launched its first biological implant, the collagen meniscus implant, CMI, in Europe. The product is a sponge-like structure of highly purified collagen. The porous structure of the CMI serves as a scaffold to support ingrowth of cells and the formation of new meniscus tissue. The product was developed jointly with Redwood, California-based ReGen Biologics, in which Sulzer has a minority holding. Sulzer, of Winterthur, Switzerland, has marketing and distribution rights to the product worldwide, excluding the US.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.